Immunisation is one the major public health achievements of the 20th century. Indeed, vaccination campaigns around the world have been responsible for the eradication of smallpox and have significantly reduced the burden of other diseases.
Population access to vaccines is essential to decrease the number of cases of common, dangerous, handicapping and potentially fatal vaccine preventable diseases. For this reason, Vaccines Europe is committed to ensuring fast and wider access of EU populations to vaccines and aims to enable better protection of health throughout life of individuals and the wider community both with existing vaccines and those on development.
Best practices for vaccine market access
Vaccines Europe is conducting a project which objective is to revise and compare NITAGs’ policies and decision-making processes for vaccine market access in both EU and non-EU countries. Read more…
Health Technology Assessment for vaccines
In the light of the current discussions at EU level on HTA, Vaccines Europe is conducting a project that seeks to identify vaccine-specific HTA related issues and conduct a gap analysis to understand the reason why vaccine-specific issues might not be addressed in current guidelines. Read more…
